The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
NF-κB in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“This process is initiated by an “angiogenic switch” in which the balance between pro-angiogenic and anti-angiogenic factors is tipped toward angiogenesis (Carmeliet and Jain 2000).”
BackgroundHershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 2×
“Overexpression of cyclin D1 and amplification or translocation of 11q13 (where CCND1 locates) are found frequently in many human cancers (Donnellan and Chetty 1998; Hunter and Pines 1994; Sherr 1996).”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“Furthermore, the constitutive activation of NF-κB leads to the production and secretion of cytokines such as IL-6 in an autocrine/ paracrine manner, which causes the consequent activation of STAT3 signaling in various human cancers (Grivennikov and Karin 2010; Hodge et al. 2005; Yu et al. 2009).”
BackgroundNF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 2×
“Various factors such as pattern recognition receptors (PRRs) (Karin 2006), tumor-promoting cytokines (Terzic et al. 2010), or casein kinase 2 (CK2) (Farah et al. 2003) have been implicated in the constitutive activation of NF-κB in colorectal cancer; however, the molecular mechanisms underlying…”
BackgroundCancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925 · cited 6×
“Activation of NF-κB is required for COX-2 production, as evidenced by the observations of impaired COX-2 expression after specific inhibition of NF-κB (Smith et al. 2000).”
BackgroundInfluentialModulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709 · cited 1×
“In IκBα-SR-expressing cells, overexpression of either Bfl-1/ A1 or Bcl-xL has been found to confer resistance to apoptosis induced by TNFα (Chen et al. 2000; Karin and Lin 2002; Zong et al. 1999).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 5×
“Bortezomib, a boronic acid dipeptide, selectively binds to and inhibits the 26S proteasome, which in turn prevents IκBα degradation, leading to the blockade of NF-κB activation (Richardson et al. 2003).”
BackgroundInfluentialAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“Thalidomide and its analogs are a group of immunomodulatory drugs that have shown therapeutic significance in treating multiple myeloma (Singhal et al. 1999).”
BackgroundThe two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390 · cited 1×
“…increase the transcription of the IκBα gene, which in turn elevates the protein level of this NF-κB inhibitor that retains NF-κB in the cytoplasm (Auphan et al. 1995; Scheinman et al. 1995); also, the ligand-activated glucocorticoid receptor can directly interact with the p65 subunit,…”
BackgroundIntegrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272 · cited 3×
“Furthermore , COX-2-mediated endothelial cell migration and tube formation could be inhibited by the selective COX-2 inhibitor NS-398 and the non-selective inhibitor aspirin (Tsujii et al. 1998).”
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 2×
“Various factors such as pattern recognition receptors (PRRs) (Karin 2006), tumor-promoting cytokines (Terzic et al. 2010), or casein kinase 2 (CK2) (Farah et al. 2003) have been implicated in the constitutive activation of NF-κB in colorectal cancer; however, the molecular mechanisms underlying…”
BackgroundCollins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., & Maniatis, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.10.7542214 · Cited by 1,718
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983
Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
Matsuoka, M., & Jeang, K.-T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2111 · Cited by 829
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., & Franzoso, G. (2001) · Nature · doi:10.1038/35104560 · Cited by 732 · cited 1×
“In addition, interference with JNK activity can be achieved through NF-κB-dependent upregulation of genes encoding inhibitors of JNK signaling such as GADD45β, XIAP, and A20 (De Smaele et al. 2001; Papa et al. 2004; Tang et al. 2001).”
BackgroundPersistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.017 · Cited by 663
Yamamoto, K., Arakawa, T., Ueda, N., & Yamamoto, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31315 · Cited by 647 · cited 16×
“COX-2 has been also found to promote colon carcinoma-induced angiogenesis by producing important angiogenic factors (Tsujii et al. 1998).”
BackgroundInfluentialHelbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
Catz, S. D., & Johnson, J. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204926 · Cited by 538
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485 · cited 1×
“In addition, the IKK-related kinase TANK-binding kinase 1 (TBK1), functioning downstream of Ras, has been shown to trigger the classical NF-κB pathway activation, as judged by the accumulation of nuclear NF-κB (Baldwin 2012; Staudt 2010).”
BackgroundTHE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Müller, M., Morotti, A., & Ponzetto, C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.4.1060-1072.2002 · Cited by 129 · cited 2×
“2005), hepatocyte growth factor (HGF)/Met signaling (Muller et al. 2002), and TAK1/IKK pathway (Arsura et al.”
Background
Cited by
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00312-6 · Cited by 2,135
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Self-citationThe multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452
Self-citationOxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review
Sethi, G., Shanmugam, M., Warrier, S., Merarchi, M., Arfuso, F., Kumar, A., & Bishayee, A. (2018) · Nutrients · doi:10.3390/nu10050645 · Cited by 253
Self-citation
Metadata
- Authors
- Li, F., Zhang, J., Arfuso, F., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., Kumar, A. P., Ahn, K. S., & Sethi, G.
- Venue
- Archives of Toxicology
- Published
- 2015-02-18
- Volume
- 89
- Issue
- 5
- Pages
- 711-731
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2128846014
- Cited by
- 198
- References
- 35
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.